Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer
The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal cancer
Colorectal Cancer
DRUG: BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|DRUG: BVZ+XELOX
progression-free survival, 2010-2014
overall survival, 2010-2014|Objective response rate, 2010-2014|% of patients whose disease becomes resectable, 2010-2014|Adverse events, 2010-2014|Evaluation of KRAS status as a molecular marker, 2010-2014
The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection, according to polymorphisms in TS-3'UTR and ERCC1-118, to be combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal cancer